<![CDATA[Taking A Cautionary View on RADICAL Trial Data in Bone-Metastatic RCC]]>

Data ReadoutnegativeNegative

AI Analysis

Summary

The RADICAL trial in bone-metastatic renal cell carcinoma was closed early due to adverse effects that outweigh secondary survival signals, according to expert commentary by Dr. María Teresa Bourlon.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

RADICAL trial closed early due to adverse effects; secondary survival signals do not outweigh safety concerns in bone-metastatic RCC

Importance:6/10

Sentiment:

-0.70

RADICAL trialbone-metastatic RCCrenal cell carcinomaadverse effectsearly closuresafety concerns

Read the original article

Published by Cancer Network on July 30, 2026 2:00 PM

Read Original